Bright Minds Biosciences Inc. (DRUG) — Bright Minds Biosciences presented at the Jefferies Global Healthcare Conference, giving management a platform to update investors on its selective serotonin (5-HT2C) agonist pipeline targeting epilepsy and neuropsychiatric disorders.
Conference visibility is meaningful for the small-cap developer, which has drawn heightened sell-side attention in 2026. The appearance is part of ongoing investor-outreach efforts around its lead clinical programs.
Source: stocktitan.net
For the rest of that week's sector news, read our week in review.